USVP healthcare team has a unique competence in investing in medical devices, biotechnology and healthcare information technology sectors, with a focus on therapeutic medical devices that enable new or less invasive procedures, molecularly targeted protein or small molecule therapeutics, and information technology-enabled healthcare services, which improve the quality of care and/or significantly reduce costs.
As of 2018, CureDuchenne’s portfolio includes 16 wide-ranging projects with 4 successful exits. Investments from CureDuchenne Ventures have successfully leveraged more than $1.3 billion in follow-on financing from venture capital, biotech, and pharmaceutical companies to fund emerging projects to find treatments for Duchenne.